 9. Prior endocrine therapy with or without a CDK 46 inhibitor unless endocrine therapy is not indicated ie, short relapse-free interval while on adjuvant endocrine therapy endocrine resistance; rapidly progressing diseasevisceral crisis; or endocrine intolerance. Any targeted therapies approved for HER2 negative, HR positive MBC, including everolimus, are permitted as prior therapy. There is no limit to the number of prior endocrine therapies. 